Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial

Semin Thromb Hemost. 2006 Apr;32(3):283-8. doi: 10.1055/s-2006-939440.

Abstract

There has been a dearth of prospective randomized studies in essential (or primary) thrombocythemia (ET). To date, only two reports have been published. Cortelazzo et al reported the first study in 1995. The second is the Medical Research Council Primary Thrombocythemia 1 trial (MRC PT-1), the results and implications of which are the subject of this article.

Publication types

  • Review

MeSH terms

  • Disease Management
  • Humans
  • Hydroxyurea / therapeutic use
  • Quinazolines / therapeutic use
  • Randomized Controlled Trials as Topic*
  • Thrombocythemia, Essential / complications
  • Thrombocythemia, Essential / therapy*
  • Treatment Outcome

Substances

  • Quinazolines
  • anagrelide
  • Hydroxyurea